IP Library › Granted Patent US 12,419,339
Granted Patent B2
US 12,419,339 · App. 17/290,322 · Granted Sep 23, 2025

Aerosolized formulation

Inventor: Ross Cabot (London, GB)
Assignee: Nicoventures Trading Limited
A24B15/167A24F40/05A24F40/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,339
App. No.
17/290,322
Granted
Sep 23, 2025
Kind
B2
Abstract

An aerosolized formulation comprising (i) water in an amount of at least 50 wt. % based on the aerosolized formulation; and (ii) at least one flavor; wherein the aerosolized formulation contains the at least one flavor in an amount of at least 70 wt % of the said flavor present in the aerosolizable formulation from which the aerosolized formulation was formed. A process for forming an aerosol comprising the aerosolizable formulation, an electronic aerosol provision system having an aerosolizer for aerosolizing the aerosolizable formulation for inhalation by a user, and a process for improving flavor to an aerosolized formulation.

Claims (25)

1. An aerosolized formulation comprising:

(i) water in an amount of at least 50 wt. % based on the aerosolized formulation; and

(ii) at least one flavor; and

(iii) one or more substituted cyclodextrins present in a total amount of from 0.001 wt. % to 8 wt. % based on the aerosolized formulation;

wherein the aerosolized formulation contains the at least one flavor in an amount of at least 70 wt. % of the at least one flavor present in an aerosolizable formulation from which the aerosolized formulation was formed, wherein an aerosol of the aerosolized formulation has the following particle size distribution: a D10 of at least 0.5 μm.

2. The aerosolized formulation according to claim 1 , wherein water is present in an amount of at least 75 wt. % based on the aerosolized formulation.

3. The aerosolized formulation according to claim 1 , wherein water is present in an amount of at least 90 wt. % based on the aerosolized formulation.

4. The aerosolized formulation according to claim 1 , wherein the at least one flavor is selected from the group consisting of (4-(para-) methoxyphenyl)-2-butanone, vanillin, γ-undecalactone, menthone, 5-propenyl guaethol, menthol, para-mentha-8-thiol-3-one and mixtures thereof.

5. The aerosolized formulation according to claim 1 , wherein the at least one flavors comprises menthol.

6. The aerosolized formulation according to claim 1 , wherein the at least one flavor is present in a total amount of no greater than 2 wt. % based on the aerosolized formulation.

7. The aerosolized formulation according to claim 1 , wherein the at least one flavor is present in a total amount of from 0.01 to 1 wt. % based on the aerosolized formulation.

8. The aerosolized formulation according to claim 1 , wherein the aerosolized formulation contains the at least one flavor in an amount of at least 80 wt. % of the at least one flavor present in the aerosolizable formulation from which the aerosolized formulation was formed.

9. The aerosolized formulation according to claim 1 , wherein the aerosolized formulation contains the at least one flavor in an amount of at least 90 wt. % of the at least one flavor present in the aerosolizable formulation from which the aerosolized formulation was formed.

10. The aerosolized formulation according to claim 1 , wherein the aerosolized formulation contains more than one flavor.

11. The aerosolized formulation according to claim 10 , wherein the aerosolized formulation contains each of the more than one flavors in an amount of at least 70 wt. % of each of the more than one flavor present in the aerosolizable formulation from which the aerosolized formulation was formed.

12. The aerosolized formulation according to claim 1 , further comprising one or more cyclodextrins present in a total amount of from 0.001 wt. % to 0.5 wt. % based on the aerosolized formulation.

13. The aerosolized formulation according to claim 1 , wherein the aerosolized formulation further comprises at least one active agent.

14. The aerosolized formulation according to claim 13 , wherein the active agent is present in an amount of no greater than 1 wt. % based on the aerosolized formulation.

15. The aerosolized formulation according to claim 13 , wherein the active agent is present in an amount of from 0.01 to 0.6 wt. % based on the aerosolized formulation.

16. The aerosolized formulation according to claim 13 , wherein the active agent comprises nicotine.

17. The aerosolized formulation according to claim 1 , wherein the aerosolized formulation further comprises an acid.

18. The aerosolized formulation according to claim 17 , wherein the acid is selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.

19. The aerosolized formulation according to claim 17 , wherein the acid is selected from the group consisting of citric acid, benzoic acid, levulinic acid, lactic acid, sorbic acid, and mixtures thereof.

20. The aerosolized formulation according to claim 17 , wherein the acid comprises citric acid.

21. The aerosolized formulation according to claim 1 , wherein the aerosolizable formulation contains no flavors that can be encapsulated by the one or more substituted cyclodextrins.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2022
From: CABOT, ROSS; BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED
To: NICOVENTURES TRADING LIMITED
Reel/Frame 061061/0154 →
Priority Claims (1)
GB 1817860 · Nov 1, 2018 · national
Continuity (1)
Related Publication 20210368852A1 · Dec 2, 2021
References Cited (234)
US 4223292A · Morikawa et al. · 1980 [cited by applicant]
US 4588976A · Jaselli · 1986 [cited by applicant]
US 4735217A · Gerth et al. · 1988 [cited by applicant]
US 4922901A · Brooks et al. · 1990 [cited by applicant]
US 4945928A · Rose · 1990 [cited by applicant]
US 5060671A · Counts et al. · 1991 [cited by applicant]
US 5095921A · Losee et al. · 1992 [cited by applicant]
US 5179966A · Losee et al. · 1993 [cited by applicant]
US 5222362A · Maus et al. · 1993 [cited by applicant]
US 5322075A · Deevi et al. · 1994 [cited by applicant]
US 5530225A · Hajaligol · 1996 [cited by applicant]
US 5613505A · Campbell et al. · 1997 [cited by applicant]
US 5666978A · Counts et al. · 1997 [cited by applicant]
US 5692525A · Counts et al. · 1997 [cited by applicant]
US 5771845A · Pistien et al. · 1998 [cited by applicant]
US 6124579A · Steinhauser et al. · 2000 [cited by applicant]
US 6155268A · Takeuchi · 2000 [cited by applicant]
US 6671450B2 · Khan et al. · 2003 [cited by applicant]
US 7374063B2 · Reid · 2008 [cited by applicant]
US 8156944B2 · Han · 2012 [cited by applicant]
US 8948578B2 · Buchberger · 2015 [cited by applicant]
US 9333229B2 · Bjorncrantz · 2016 [cited by applicant]
US 9655890B2 · Hearn et al. · 2017 [cited by applicant]
US 10449308B2 · Buchberger · 2019 [cited by applicant]
US 10602777B2 · Dickens et al. · 2020 [cited by applicant]
US 11064726B2 · Fujisawa et al. · 2021 [cited by applicant]
US 11089660B2 · Wensley · 2021 [cited by examiner]
US 20010009660A1 · Delli Santi et al. · 2001 [cited by applicant]
US 20020113685A1 · Izaki et al. · 2002 [cited by applicant]
US 20030049025A1 · Neumann et al. · 2003 [cited by applicant]
US 20030159702A1 · Lindell et al. · 2003 [cited by applicant]
US 20030186474A1 · Haluzak et al. · 2003 [cited by applicant]
US 20040034068A1 · Warchol et al. · 2004 [cited by applicant]
US 20040096204A1 · Gerhardinger · 2004 [cited by applicant]
US 20040156792A1 · Tarara et al. · 2004 [cited by applicant]
US 20040247302A1 · Toya et al. · 2004 [cited by applicant]
US 20050063686A1 · Whittle et al. · 2005 [cited by applicant]
US 20050211711A1 · Reid · 2005 [cited by applicant]
US 20050241656A1 · Kennison · 2005 [cited by examiner]
US 20050268911A1 · Cross et al. · 2005 [cited by applicant]
US 20070031343A1 · Bonfour, III · 2007 [cited by examiner]
US 20070074734A1 · Braunshteyn et al. · 2007 [cited by applicant]
US 20070155255A1 · Galauner et al. · 2007 [cited by applicant]
US 20070267033A1 · Mishra et al. · 2007 [cited by applicant]
US 20080047956A1 · Dudman · 2008 [cited by applicant]
US 20080138399A1 · Gonda · 2008 [cited by applicant]
US 20080216828A1 · Wensley et al. · 2008 [cited by applicant]
US 20080286340A1 · Andersson et al. · 2008 [cited by applicant]
US 20090126745A1 · Hon · 2009 [cited by applicant]
US 20090220222A1 · Rabin et al. · 2009 [cited by applicant]
US 20090272379A1 · Thorens et al. · 2009 [cited by applicant]
US 20100126520A1 · Clayton · 2010 [cited by applicant]
US 20110155153A1 · Thorens et al. · 2011 [cited by applicant]
US 20110226236A1 · Buchberger · 2011 [cited by applicant]
US 20130081623A1 · Buchberger · 2013 [cited by applicant]
US 20130192623A1 · Tucker et al. · 2013 [cited by applicant]
US 20140182608A1 · Egoyants et al. · 2014 [cited by applicant]
US 20150030317A1 · Bayer et al. · 2015 [cited by applicant]
US 20150040925A1 · Saleem et al. · 2015 [cited by applicant]
US 20150059780A1 · Davis et al. · 2015 [cited by applicant]
US 20160157521A1 · Woodcock et al. · 2016 [cited by applicant]
US 20160198759A1 · Kuntawala · 2016 [cited by examiner]
US 20160338407A1 · Kerdemelidis · 2016 [cited by applicant]
US 20160345621A1 · Li et al. · 2016 [cited by applicant]
US 20170119040A1 · Cameron · 2017 [cited by applicant]
US 20170119051A1 · Blandino et al. · 2017 [cited by applicant]
US 20170215476A1 · Dickens et al. · 2017 [cited by applicant]
US 20170303594A1 · Cameron et al. · 2017 [cited by applicant]
US 20170325494A1 · Cameron et al. · 2017 [cited by applicant]
US 20180071274A1 · Havercroft et al. · 2018 [cited by applicant]
US 20180199618A1 · Fuisz et al. · 2018 [cited by applicant]
US 20180279667A1 · McAdam et al. · 2018 [cited by applicant]
US 20180279679A1 · McAdam et al. · 2018 [cited by applicant]
US 20180304031A1 · Havercroft et al. · 2018 [cited by applicant]
US 20190116863A1 · Dull · 2019 [cited by applicant]
US 20210177040A1 · Dickens et al. · 2021 [cited by applicant]
US 20210196700A1 · Nolan · 2021 [cited by examiner]
US 20210378282A1 · Cabot · 2021 [cited by applicant]
US 20210386110A1 · Cabot · 2021 [cited by applicant]
US 20210386111A1 · Cabot · 2021 [cited by applicant]
US 20220000167A1 · Cabot · 2022 [cited by applicant]
US 20220071267A1 · Cabot · 2022 [cited by applicant]
US 20220132906A1 · McAdam et al. · 2022 [cited by applicant]
US 20230165299A1 · Cabot · 2023 [cited by applicant]
US 20230180818A1 · Cabot · 2023 [cited by applicant]
US 20230270154A1 · Cabot · 2023 [cited by applicant]
AU 6195998A · 1998 [cited by applicant]
AU 717600B2 · 2000 [cited by applicant]
AU 2019276357A1 · 2020 [cited by applicant]
AU 2019371079B2 · 2022 [cited by applicant]
CN 1708241A · 2005 [cited by applicant]
CN 1741789A · 2006 [cited by applicant]
CN 101390659A · 2009 [cited by applicant]
CN 101404902A · 2009 [cited by applicant]
CN 101583354A · 2009 [cited by applicant]
CN 201375023Y · 2010 [cited by applicant]
CN 102753047A · 2012 [cited by applicant]
CN 104585866A · 2015 [cited by applicant]
CN 104970445A · 2015 [cited by applicant]
CN 105029677A · 2015 [cited by applicant]
CN 105979805A · 2016 [cited by applicant]
CN 106413697A · 2017 [cited by applicant]
CN 106572706A · 2017 [cited by applicant]
CN 107105756A · 2017 [cited by applicant]
CN 107529828A · 2018 [cited by applicant]
CN 107949284A · 2018 [cited by applicant]
CN 108289496A · 2018 [cited by applicant]
CN 108323827A · 2018 [cited by applicant]
DE 102015117811 · 2017 [cited by applicant]
EP 2110033A1 · 2009 [cited by applicant]
EP 2316286A1 · 2011 [cited by applicant]
EP 2340729A1 · 2011 [cited by applicant]
EP 2842640A1 · 2015 [cited by applicant]
EP 3574902 · 2019 [cited by applicant]
GB 2569940A · 2019 [cited by applicant]
JP H03277265A · 1991 [cited by applicant]
JP H0462094U · 1992 [cited by applicant]
JP H1189551A · 1999 [cited by applicant]
JP 2004298331A · 2004 [cited by applicant]
JP 2005511178A · 2005 [cited by applicant]
JP 2005533770A · 2005 [cited by applicant]
JP 2009525746A · 2009 [cited by applicant]
JP 2009537120A · 2009 [cited by applicant]
JP 2010516243A · 2010 [cited by applicant]
JP 2011229481A · 2011 [cited by applicant]
JP 2012210223A · 2012 [cited by applicant]
JP 2014526240A · 2014 [cited by applicant]
JP 2014532437A · 2014 [cited by applicant]
JP 2016073307A · 2016 [cited by applicant]
JP 2016526873A · 2016 [cited by applicant]
JP 2017523785A · 2017 [cited by applicant]
JP 2017536816A · 2017 [cited by applicant]
JP 2021523256A · 2021 [cited by applicant]
JP 2021526147A · 2021 [cited by applicant]
JP 2022506068A · 2022 [cited by applicant]
JP 2022506094A · 2022 [cited by applicant]
KR 20120101118A · 2012 [cited by applicant]
KR 20160008271A · 2016 [cited by applicant]
NZ 536863A · 2007 [cited by applicant]
RU 2048780C1 · 1995 [cited by applicant]
RU 2070062C1 · 1996 [cited by applicant]
RU 2336001C2 · 2008 [cited by applicant]
RU 2536115C2 · 2014 [cited by applicant]
RU 2542547C2 · 2015 [cited by applicant]
RU 2607535C2 · 2017 [cited by applicant]
RU 2653467C2 · 2018 [cited by applicant]
RU 2655188C2 · 2018 [cited by applicant]
RU 2666666C1 · 2018 [cited by applicant]
RU 2736854C1 · 2020 [cited by applicant]
WO 199109599A1 · 1991 [cited by applicant]
WO 0167819A1 · 2001 [cited by applicant]
WO 03037412A2 · 2003 [cited by applicant]
WO 03049535A1 · 2003 [cited by applicant]
WO 03055486A1 · 2003 [cited by applicant]
WO 03101454A1 · 2003 [cited by applicant]
WO 03103387A2 · 2003 [cited by applicant]
WO 2004060351A2 · 2004 [cited by applicant]
WO 2004076289A2 · 2004 [cited by applicant]
WO 2007091181A2 · 2007 [cited by applicant]
WO 2007138462A2 · 2007 [cited by applicant]
WO 2008069972A2 · 2008 [cited by applicant]
WO 2008069970A3 · 2008 [cited by applicant]
WO 2008146543A1 · 2008 [cited by applicant]
WO 2010045671A1 · 2010 [cited by applicant]
WO 2010107613A1 · 2010 [cited by applicant]
WO 2011045609A1 · 2011 [cited by applicant]
WO 2011079932A1 · 2011 [cited by applicant]
WO 2013034488A2 · 2013 [cited by applicant]
WO 2013068304A1 · 2013 [cited by applicant]
WO 2013161987A1 · 2013 [cited by applicant]
WO 2014140320A1 · 2014 [cited by applicant]
WO 2014187770A2 · 2014 [cited by applicant]
WO 2015006465A1 · 2015 [cited by applicant]
WO 2015009862A3 · 2015 [cited by applicant]
WO 2015177252A1 · 2015 [cited by applicant]
WO 2016020675A1 · 2016 [cited by applicant]
WO 2016071705A1 · 2016 [cited by applicant]
WO 2016096745A1 · 2016 [cited by applicant]
WO 2016115250A1 · 2016 [cited by applicant]
WO 2016145072A1 · 2016 [cited by applicant]
WO 2017103136A1 · 2017 [cited by applicant]
WO 2017175218A2 · 2017 [cited by applicant]
WO 2018023890A1 · 2018 [cited by applicant]
WO 2018064032A1 · 2018 [cited by applicant]
WO 2019086856A1 · 2019 [cited by applicant]
WO WO2019086858 · 2019 [cited by applicant]
WO 2020089637A1 · 2020 [cited by applicant]
WO 2020089640A1 · 2020 [cited by applicant]
International Search Report and Written Opinion for PCT/GB2019/053094 date mailed Feb. 4, 2020. [cited by applicant]
Application and File History for U.S. Appl. No. 14/382,198, filed Aug. 29, 2014, inventors Saleem et al. [cited by applicant]
British and European Pharmacopoeia 6.0, “2.9.31 Particle Size Analysis by Laser Light Diffraction,” British Pharmacopoeia Commission (2014), Stationery Office and Council of Europe (2013), pp. 311-314. [cited by applicant]
Clayton P.M., et al., “Spectroscopic Investigations into the Acid-Base Properties of Nicotine at Different Temperatures,” Analytical Methods, 2013, vol. 5, pp. 81-88. [cited by applicant]
Davies, et al., “Metallic Foams: Their Production, Properties and Applications,” Journal of Materials Science, 1983, vol. 18(7), pp. 1899-1911. [cited by applicant]
Examination Report No. 2 for Australian Application No. 2019370810, mailed on Jun. 15, 2022, 4 pages. [cited by applicant]
First Office Action and Search Report for Chinese Patent Application No. 2019800769594, mailed on Mar. 8, 2022, 14 pages. [cited by applicant]
First Office Action and Search Report for Chinese Patent Application No. 2019800779026, mailed on Mar. 28, 2022, 9 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/AT2011/000123, mailed Sep. 20, 2012, 6 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/GB2019/053094, mailed on Nov. 25, 2020, 6 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2013/057539, mailed on Feb. 11, 2014, 16 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/GB2019/053092, mailed on Feb. 4, 2020, 10 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/GB2019/053095, mailed on Feb. 4, 2020, 13 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/GB2019/053084 date mailed Feb. 4, 2020, 13 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/AT2011/000123, mailed on Jul. 18, 2011, 8 pages. [cited by applicant]
Notice of Acceptance mailed Mar. 23, 2022 for Australian Patent Application No. 2019370808, 3 pages. [cited by applicant]
Office Action mailed Sep. 29, 2015 for Japanese Application No. 2015-506185 filed Apr. 11, 2013, 5 pages. [cited by applicant]
Office Action and Search Report for Chinese Application No. 201980069806.7, mailed on Feb. 9, 2022, 20 pages. [cited by applicant]
Office Action and Search Report mailed Dec. 8, 2021 for Russian Application No. 2021112089, 15 pages. [cited by applicant]
Office Action for Chinese Application No. 201980075317.2., mailed on Feb. 23, 2022, 9 pages. [cited by applicant]
Office Action for Chinese Application No. 201980075317.2., mailed on Jun. 29, 2022, 18 pages. [cited by applicant]
Office Action for Japanese Application No. 2021-522532, mailed on Jul. 26, 2022, 10 pages. [cited by applicant]
Office Action for Japanese Application No. 2021-523220, mailed on Aug. 2, 2022, 13 pages. [cited by applicant]
Office Action for Japanese Application No. 2021-523226, mailed on Jul. 26, 2022, 13 pages. [cited by applicant]
Office Action mailed Jul. 26, 2020 for Japanese Application No. 2021-523256, 13 pages. [cited by applicant]
Search Report for Japanese Application No. 2021-522532, mailed Jul. 20, 2022, 58 pages. [cited by applicant]
Search Report for Russian Application No. 2021112009, mailed Dec. 27, 2021, 2 pages. [cited by applicant]
Search Report for Russian Application No. 2021112073 mailed on Dec. 14, 2021, 2 pages. [cited by applicant]
Search Report for Russian Application No. 2021112078 mailed on Jan. 26, 2022, 3 pages. [cited by applicant]
Search Report mailed Oct. 15, 2014 for Japanese Application No. 2012-556343, 18 pages. [cited by applicant]
Warrier M., et al., “Effect of the Porous Structure of Graphite on Atomic Hydrogen Diffusion and Inventory,” Nucl. Fusion, vol. 47, 2007, pp. 1656-1663. [cited by applicant]
“Decision of Refusal received for Japanese Patent Application No. 2021-522532, mailed on Jan. 4, 2023”, 8 pages (4 pages of English Translation and 4 pages of Official Copy). [cited by applicant]
“Decision of Refusal received for Japanese Patent Application No. 2021-523256, mailed on Feb. 21, 2023”, 8 pages (4 pages of English Translation and 4 pages of Official Copy). [cited by applicant]
“International Preliminary Report on Patentability received for PCT Patent Application No. PCT/GB2019/053084, mailed on May 14, 2021”, 8 Pages. [cited by applicant]
“International Preliminary Report on Patentability received for PCT Patent Application No. PCT/GB2019/053092, mailed on May 14, 2021”, 7 Pages. [cited by applicant]
“International Preliminary Report on Patentability received for PCT Patent Application No. PCT/GB2019/053095, mailed on May 14, 2021”, 7 Pages. [cited by applicant]
“Notice of Allowance received for Chinese Patent Application No. 201980076959.4, mailed on Sep. 5, 2022”, 6 pages (2 pages of English Translation and 4 pages of Official Copy). [cited by applicant]
“Notice of Reasons for Refusal received for Japanese Patent Application No. 2021-523226 mailed on Feb. 21, 2023”, 8 pages (4 pages of English Translation and 4 pages of Official Copy). [cited by applicant]
“Office Action received for Canadian Patent Application No. 3,118,059, mailed on Jun. 15, 2023”, 5 pages. [cited by applicant]
“Report of Reconsideration by Examiner before Appeal for Japanese Patent Application No. 2021-522532, dated Jun. 13, 2023”, 5 pages (2 pages of English Translation and 3 pages of Official Copy). [cited by applicant]
Bair, W. J., et al., The Report of a Task Group Committee 2, the Human Respiratory Tract Model, Annals of the ICRP, ICRP Publication 66, 1994, 492 pages, vol. 24, Nos. 1-3, Pergamon Press ISSN 0146-6453. [cited by applicant]
Shekunov, B.Y., et al., Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications, Feb. 2007, 25 pages, vol. 24, Pharmaceutical Research, DOI: 10.1007/s111095-006-9146-7, Springer Science+Business Me… [cited by applicant]
Martin, A.R., et al., Nebulizers for Drug Delivery to the Lungs: Expert Opinion on Drug Delivery, abstract only, Dec. 23, 2014, 4 pages, Taylor & Francis Online, London, United Kingdom. [cited by applicant]
Non-Final Office Action, U.S. Appl. No. 14/927,556, dated Dec. 27, 2017, 9 pages, U.S. Patent and Trademark Office, Alexandria, Virginia. [cited by applicant]
Shekunov et al., “Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications”, Pharmaceutical Research, vol. 24, No. 2, pp. 203-227, Feb. 2007 DOI: 10.1007/s11095-006-9146-7. [cited by applicant]
A. R. Martin and W.H. Finlay, “Nebulizers for drug delivery to the lungs”, Expert Opinion on Drug Delivery, vol. 12, No. 6, pp. 889-900, Dec. 2014 DOI:10.1517/17425247.2015.995087. [cited by applicant]